Silence Therapeutics PLC (SLN) intrinsic value & 10-year financials
Silence Therapeutics PLC (SLN) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 9 fiscal years revenue grew 14.8% a year to £559.0K, with an average return on invested capital of 75.0%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- £8.68
- Market cap
- £1.2B
- Revenue (FY2025)
- £559.0K
- Revenue growth (9-yr CAGR)
- 14.8%
- ROIC (10-yr avg)
- 75.0%
- Free cash flow (FY2025)
- -£62.3M
SLN 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | £559.0K | -£88.6M | -£0.63 | -£62.3M | -16292.8% | -285.5% |
| FY2024 | £43.3M | -£45.3M | -£0.33 | -£67.9M | -146.4% | 372.6% |
| FY2023 | £31.6M | -£54.2M | -£0.49 | -£49.5M | -203.5% | 137.9% |
| FY2022 | £21.7M | -£50.3M | -£0.52 | -£57.2M | -281.9% | — |
| FY2021 | £12.4M | -£39.4M | — | £5.5M | -369.0% | — |
| FY2020 | £5.3M | -£32.5M | — | -£11.3M | -676.4% | — |
| FY2019 | £244.0K | -£19.6M | — | £1.7M | -9317.2% | — |
| FY2018 | — | -£18.4M | — | -£16.9M | — | — |
| FY2017 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in GBP.
Executive summary
Silence Therapeutics plc revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Silence Therapeutics plc has earned high returns on invested capital, averaging 46.3% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Silence Therapeutics plc capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Silence Therapeutics plc is modeled at 14.8% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-20.73 per share.